Letter by Xie et al Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial"

Circulation. 2019 May 28;139(22):e1015-e1016. doi: 10.1161/CIRCULATIONAHA.118.039071. Epub 2019 May 28.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cardiovascular Diseases*
  • Diabetes Mellitus, Type 2*
  • Humans
  • Hypoglycemic Agents
  • Liraglutide
  • Renal Insufficiency, Chronic*

Substances

  • Hypoglycemic Agents
  • Liraglutide